The present invention relates to new ophthalmic pharmaceutical compositions for use in the treatment of the dry eye syndrome, comprising hydrocortisone or a pharmaceutically acceptable salt thereof in an amount equal to or greater than 0.0005% by weight and less than 0.003% by weight and a lacrimal substitute.